Announcements

June 2024: Lipomedix Pharmaceuticals Ltd. received the Ethical Committee Israel Medical Sites clearance to launch a Phase 2A clinical trial to test the safety and efficacy of Promitil for the treatment of patients with solid tumors associated with deleterious mutations who have progressed after first line therapy, PROM-2301 (NCT06478862).
March 2024: The Canadian Patent Office has granted Lipomedix patent (#2985330) entitled "Methods for the Treatment of Bladder Cancer".
January 2022: Lipomedix Pharmaceuticals Ltd. completed LIPORAD-2018 (NCT03823989), a multi-center, open-label, single-arm, prospective study, in patients requiring RT for metastatic disease or for an inoperable primary tumor with no definitive curative treatment option. The clinical study report (CSR) was released. See link in Publications.
May 2021: The European Patent Office has granted Lipomedix patent (#3270898) entitled "Methods for the Treatment of Bladder Cancer".
March 2021: The Japanese Patent Office has granted Lipomedix patent (#6859275) entitled "Methods for the Treatment of Bladder Cancer".
November 2020: Lipomedix Pharmaceuticals has been awarded the Seal of Excellence for the project "A unique ‘smart’ nanomedicine for a safer and more effective chemo-radiotherapy" submitted under the Horizon 2020’s SME Instrument call H2020-EIC-SMEInst-2018-2020.
August 2020: The European Patent Office has granted Lipomedix patent (#3151863) entitled "Combination Therapy Comprising A Liposomal Prodrug of Mitomycin C and Radiotherapy".
April 2020: The USPTO has granted Lipomedix patent (#10617672) entitled "Liposome Composition Co-Encapsulating Doxorubicin and A Prodrug of Mitomycin C".
July 2019: Lipomedix Pharmaceuticals has been awarded the SME Horizon 2020 Phase 1 grant for the project: Promitil® - a new ‘smart’ nanomedicine for cancer chemo-radiotherapy.
November 2018: Lipomedix Pharmaceuticals Ltd. announces the Israeli Ministry of Health clearance to launch a Phase 1b clinical trial of Promitil in combination with external beam radiotherapy in patients with advanced cancer requiring palliative radiotherapy for inoperable primary tumors or metastatic disease. The study (LIPORAD-18) will be launched soon and conducted by investigators in two Medical Centers in Israel.
September 2018: Lipomedix received the approval of a new USPTO (#10080807) for the combined use of Promitil with other chemotherapy entitled "Combination Chemotherapy Comprising a Liposomal Prodrug of Mitomycin C".
April 2018: Lipomedix received the approval of a new USPTO (#9937261) for the combined use of Promitil with Radiotherapy entitled “Combination Therapy Comprising a Liposomal Prodrug of Mitomycin C and Radiotherapy”.
May 2016: Lipomedix received a 2 million NIS grant from the Israel Chief Scientist Office for the funding of the project “Development of Promitil a pegylated liposomal MMC- prodrug”.

Presentations

October 2023: Dr. Alberto Gabizon, lectured at the 14th European and Global Summit for Nanomedicine (CLINAM 2023) in Basel, Switzerland, on " Development of Promitil®, a Lipidic Prodrug of Mitomycin c in Pegylated Liposomes: From Bench to Bedside".

May 2022: "Pegylated liposomal mitomycin C lipidic prodrug and radiotherapy in advanced cancer patients (pts) – a Phase 1B study" poster was presented at the ESTRO 2022 meeting in Copenhagen, Denmark.

October 2020: Dr. Gabizon, President and Chief Scientist of Lipomedix, lectured at 12th European and Global Summit for Nanomedicine (CLINAM 2020), on “Pharmacokinetic and Clinical Correlations of Pegylated Liposomal Mitomycin c Prodrug (Promitil) in Colorectal Cancer Patients.”

September 2019: The President and Chief Scientist of Lipomedix, Professor Gabizon, lectured at the Liposome Research Days 2019 Conference in Sapporo, Hokkaido , Japan, on "Promitil® - a lipidic prodrug of mitomycin c in liposomes: From bench to bedside."

April 2019: Poster entitled “Clinical and pharmacokinetic study with a lipidic prodrug of mitomycin c entrapped in liposomes in metastatic colorectal cancer patients” was presented at the American Association for Cancer Research (AACR), annual meeting, in Atlanta, Georgia, USA.

Investors

Lipomedix is majority owned by Rafael Holdings, Inc. We are always seeking additional funding from private investors or investment groups for advancing the clinical development of Promitil®, and for further developing its pipeline. Prospective investors are invited to meet with the Company’s management team to discuss an investment in the Company.